Clinical Research and Trials

Clinical research studies are vital to the process of discovering the safest and most effective cancer therapies for patients. The C.R. Wood Cancer Center currently has approximately 40 national clinical studies available for treatment, quality of life and prevention of different cancers. Glens Falls Hospital has partnered with the University of Vermont for shared opportunities in their clinical studies, and the center also participates in clinical studies directly through pharmaceutical companies. The physicians and staff of the C.R. Wood Cancer Center work closely with these well respected organizations, along with the National Cancer Institute, to provide opportunities for local patients to take part in national clinical research studies, without having to travel away from home. These studies provide the opportunity for patients to conveniently receive some of the most cutting edge therapies available, while also allowing them to directly contribute to the ongoing progress being made in the field of oncology. Treatment studies may consist of chemotherapy, immunotherapy, radiation therapy, hormonal therapy or combination therapy.

For more information on clinical studies, contact Beth Ann Brundage, RN, OCN, at 518-926-6644 or Nannette Oberhelman, at 518-926-6701.

Clinical Trials

ANAL

CTSU EA2165
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Ca

BILIARY

CTSU  S1815   
A Phase III Randomized Trial Of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers

BLADDER

CTSU    A031501 
Phase III randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma (AMBASSADOR) versus observation

BREAST

CTSU A011502  
A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: the ABC Trial

CTSU    A221505-CHARM
Randomized trial testing the safety and patient experience of short course radiation after mastectomy and breast reconstruction for breast cancer

CTSU S171601
A Phase II Trial Assessing the tolerability of Palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor positive, HER-2 negative metastatic breast cancer

CTSU NRG-BR003
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

P Registry
Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been  recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer. (Also under Registries)

HEPATOCELLULAR

P REFINE/19244
Regorafenib Observational Study in hepatocellular carcinoma

LEUKEMIA

CTSU A041702
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

CTSU EA9161
A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab vs Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

SCLC Limited

C 30610
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposid

NSCLC Limited

CTSU A151216  NSCLC
Genetic Testing For Patients with Resectable or Resected Lung Cancer (ALCHEMIST)

CTSU E4512 
A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. (ALCHEMIST)

CTSU A081105  Alchemist
A Phase III Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC (ALCHEMIST)

NSCLC Advanced

CTSU  LUNGMAP
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

LEUKEMIA

P Registry informCLL™
A Disease Registry for Patients with Chronic Lymphocytic Leukemia (also under Registries)

MDS

NHLBI-MDS 
The National Myelodysplastic Syndromes (MDS) Study: Recruiting Patients With Low Blood Counts Undergoing A Bone Marrow Assessment for Evaluation of MDS

MULTIPLE MYELOMA

P Amgen Inc. Amgen-Pro00028973/20170758
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia among Subjects with Non-myeloid Malignancies at High Risk for Febrile Neutropenia and receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of Febrile Neutropenia

CTSU EAA173   DETER-SMM
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

RARE TUMORS

CTSU S1609 DART Study
Dual Anti-CTLA-4 and Anit-PD-1 Blockade in Rare Tumors

RECTAL

NRG GI002
Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer (Temporarily Closed to Accrual)

RENAL

A031704
Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

CTSU EA8143  
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

PREVENTION

CTSU S0820
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers s/p one year after primary resection in Patients with Stage 0-III Colon Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

REGISTRIES

P Registry
Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been  recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer.

NOTE:  Other studies are available to us through the University of VT; we open them as Research Nurse identifies an eligible patient.

C.R. Wood Cancer Center
Research Office

Pruyn Pavilion at Glens Falls Hospital
2nd Floor
100 Park Street
Glens Falls, NY 12801

Phone: 518-926-6701
Fax: 518-926-1954

Clinical Trial Key:

A = Alliance

C = CALGB

E = ECOG

N = NSABP

NRG = NSABP/RTOG/GOG

P = Pharmacy

R = RTOG

S = SWOG

CTSU= NCI Cancer Trials Support Unit

VCC = Vermont Cancer Center

 

Updated 8/2019